###### Strengths and limitations of this study

-   We developed and internally validated a risk model predicting in-hospital mortality using a nationally representative sample of \>650 000 patients who underwent percutaneous coronary intervention (PCI) in Japan to provide risk-adjusted mortality in a benchmark reports.

-   For clinical use, the 'preprocedure' risk model that did not require procedure-related variables and a simplified integer risk score based on the preprocedure model were also developed and internally validated, aiding in stratifying patients at risk of death preprocedurally.

-   Several variables selected in other risk models were not included in the Japanese-PCI registry and could further refine risk prediction.

-   The models underestimated the risk of mortality and could not provide an accurate estimation in the elective procedure, mainly owing to the small number of in-hospital deaths.

Background {#s1}
==========

In Japan, percutaneous coronary interventions (PCIs) are widely available for both elective and acute settings, and \>200 000 procedures are performed annually in \>1000 hospitals. On the advent of technology and technique in interventional cardiology, the current in-hospital mortality rate is about 1%.[@R1] However, PCI is applied onto a wide spectrum of coronary artery disease, and its indication varies substantially across hospitals, especially between low-volume and high-volume centres, suggesting an opportunity for improvement.[@R1] Adjusted risk mortality is a core component of performance measures and used even for public reporting[@R3]; therefore, adjustment for the variation in patient risk across hospitals is critically important to enable an accurate assessment of each hospital's performance and opportunity to improve.

A number of risk prediction models for short-term mortality after PCI were developed within the last decade.[@R4] However, almost all of them share certain limitations: (1) they were not validated, (2) they were derived from small studies and (3) the parameters used cannot be easily assessed directly in the catheterisation laboratory. Furthermore, given the favourable patient and laboratory profile (eg, lesser risk of bleeding) for percutaneous procedures among the East Asian patients, PCI is performed onto significantly complex and 'sicker' group of patients in Japan. Hence, it remains a challenge for clinicians to use these existing models for the risk adjustment due to the differences in biological responses to medication or procedure among ethnicities and practice pattern among counties.[@R10]

The risk prediction model from its own dataset is mandatory, especially when considering the adjustment for mortality in a benchmark, eventually leading to improve quality of care in PCIs. Using the nationwide Japanese-PCI registry (J-PCI), this study aimed (1) to develop two separate PCI risk prediction models for estimating in-hospital mortality that can be applied to both acute and elective clinical settings, one based on all available variables including both preprocedure and procedure-related variables, and the other based on preprocedural variables only; (2) to internally validate the developed risk models and (3) to develop and validate a clinician-friendly simplified integer risk score to enable pre-PCI risk stratification in clinical care.

Methods {#s2}
=======

Data source {#s2a}
-----------

We analysed patients who underwent PCI between January 2014 and December 2016 (n=680 947) and were registered in the J-PCI. The J-PCI was established in 2007 and is a prospective Japanese nationwide multicentre registry of the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT) designed to collect clinical variables and in-hospital outcome data on PCI patients.[@R1] Variables regarding patient background, clinical presentation, angiographic and procedure-related information, and in-hospital outcomes were collected from each patient. The CVIT registry subcommittee designed the software for the web-based data collection system, and each data manager in the participating hospitals submits data through this system annually. As registration in the J-PCI database is mandatory for the application for board certification and renewal, although participation in the J-PCI is voluntary, there is a high degree of data completeness. According to the annual reports of the Japanese Registry of All Cardiac and Vascular Disease, 773 359 PCIs (209 920 PCIs for acute indications and 563 439 PCIs for non-acute indications) were performed during the current study period (<http://www.j-circ.or.jp/jittai_chosa/>, accessed on 14 February2018). Since we included a total of 680 947 PCIs, approximately 88% of all procedures in Japan were estimated to be registered in our registry. The accuracy of submitted data is maintained by data auditing (20 institutions annually), which is operated by members of the CVIT registry subcommittee.

Written informed consent was waived due to the retrospective nature of the study.

Data definitions {#s2b}
----------------

The primary outcome measure of the J-PCI analysis was in-hospital mortality, which was defined as all-cause mortality during hospitalisation. Cardiogenic shock was defined as a sustained episode of systolic blood pressure \<80 mm Hg and/or a cardiac index of \<1.8 L/min/m^2^ (regardless of the measurement methods) despite the maximum treatment determined to be secondary to cardiac dysfunction, and/or the need for parenteral inotropic or vasopressor agents or mechanical support, including an intra-aortic balloon pump to maintain blood pressure and cardiac index above the specified levels within 24 hours prior to the initiation of PCI. In this registry, renal dysfunction was defined as the presence of proteinuria including microalbuminuria, serum creatinine≥1.3 mg/dL or estimated glomerular filtration rate ≤60 mL/min/1.73 m^2^ according to the Japanese Society of Nephrology guidelines.[@R16] The other definitions of J-PCI variables are available online (<http://www.cvit.jp/registry/jpci_definition.pdf>, accessed on 14 February 2018).

Statistical analysis {#s2c}
--------------------

The study cohort was randomly divided in a 1:1 ratio into derivation (n=334 591) and validation (n=334 590) cohorts. The demographic data and clinical patient characteristics were summarised by enrolment year, and the data were presented as mean±SD or as proportion (%), depending on the variables. Trend tests were performed using the Cochran-Armitage test for trend.

All variables in [table 1](#T1){ref-type="table"} except for procedure details were listed as initial candidate variables. Age was considered as a continuous variable, while the others were considered as dichotomous variables. With regard to diagnosis, unstable angina, ST-elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) were included in the list of candidate variables based on clinical judgement. After accounting for multicollinearity among candidate variables, final candidates for inclusion in the multivariable model were selected as follows: age, sex, clinical presentation (unstable angina, STEMI and NSTEMI), previous PCI, previous coronary artery bypass grafting, previous myocardial infarction (MI), diabetes, hypertension, dyslipidaemia, smoker, renal dysfunction (renal dysfunction without requiring dialysis and renal dysfunction on dialysis), chronic lung disease, peripheral vascular disease, previous heart failure, cardiogenic shock within 24 hours prior to the procedure, number of diseased vessel (two-vessel disease, three-vessel disease and left main trunk lesion) and involvement of the left anterior descending artery or left main trunk as a target lesion. Age was considered as a continuous variable, while the others were considered as dichotomous variables. Multivariable logistic regression with a backward selection method was then performed to identify independent predictors of in-hospital death. Package 'step' in R was used for backward selection, in which the elimination process was based on Akaike's information criterion.

###### 

Baseline characteristics by enrolment year

                                          Japanese-PCI (J-PCI) 2014   J-PCI 2015           J-PCI 2016           P value
  --------------------------------------- --------------------------- -------------------- -------------------- ---------
  Demographics                                                                                                  
    Age, years, mean (SD)                 69.97 (10.99)               70.08 (11.04)        70.26 (11.07)        \<0.001
    Female                                50 747 (24.1)               52 048 (23.9)        57 677 (24.0)        0.218
  Diagnosis                                                                                                     \<0.001
    Elective setting                                                                                            
     Stable angina                        80 244 (38.1)               83 258 (38.2)        91 894 (38.2)        
     Silent ischaemic heart disease       33 550 (15.9)               36 431 (16.7)        41 764 (17.4)        
     Old myocardial infarction            12 528 (6.0)                13 034 (6.0)         14 152 (5.9)         
    Acute setting                                                                                               
     Unstable angina                      33 985 (16.1)               33 582 (15.4)        37 599 (15.6)        
     Myocardial infarction (MI)           50 237 (23.9)               51 684 (23.7)        55 239 (23.0)        
      STEMI                               39 140 (18.6)               40 050 (18.4)        41 740 (17.3)        
      NSTEMI                              9217 (4.4)                  9844 (4.5)           11 453 (4.8)         
  Risk factors                                                                                                  
    Previous PCI                          96 877 (46.2)               99 896 (46.6)        110 163 (46.5)       0.022
    Previous CABG                         8871 (4.2)                  8525 (4.0)           8949 (3.8)           \<0.001
    Previous MI                           48 620 (23.4)               49 547 (23.3)        54 073 (22.9)        0.001
    Diabetes mellitus                     90 152 (42.8)               94 250 (43.2)        105 066 (43.7)       \<0.001
    Hypertension                          155 985 (74.1)              162 075 (74.4)       178 889 (74.3)       0.083
    Dyslipidaemia                         130 740 (62.1)              137 264 (63.0)       153 059 (63.6)       \<0.001
    Current smoker                        64 368 (30.6)               67 385 (30.9)        74 027 (30.8)        0.054
    Renal insufficiency                   35 366 (16.8)               37 857 (17.4)        43 460 (18.1)        \<0.001
     On dialysis                          13 099 (6.2)                13 649 (6.3)         15 601 (6.5)         \<0.001
    Chronic lung disease                  3347 (1.6)                  4039 (1.9)           5336 (2.2)           \<0.001
    Peripheral vascular disease           13 273 (6.3)                15 169 (7.0)         18 064 (7.5)         \<0.001
    Previous heart failure                26 105 (12.8)               27 667 (13.1)        31 478 (13.4)        \<0.001
    Cardiopulmonary arrest on arrival     3285 (1.6)                  3311 (1.6)           4137 (1.7)           \<0.001
    Cardiogenic shock within 24 hours     6023 (2.9)                  6307 (3.0)           7429 (3.1)           \<0.001
    Acute heart failure within 24 hours   8217 (4.0)                  8082 (3.8)           9347 (4.0)           0.001
  Lesion characteristics                                                                                        
   No of diseased vessels                                                                                       
    One-vessel disease                    126 593 (60.1)              133 649 (61.3)       150 477 (62.5)       \<0.001
    Two-vessel disease                    55 997 (26.6)               56 117 (25.7)        60 936 (25.3)        \<0.001
    Three-vessel disease                  27 205 (12.9)               27 371 (12.6)        28 424 (11.8)        \<0.001
    Left main trunk                       8322 (4.0)                  9129 (4.2)           9688 (4.0)           \<0.001
   Lesion location                                                                                              
    RCA                                   73 309 (34.8)               74 356 (34.1)        81 482 (33.9)        \<0.001
    LAD/left Main                         106 996 (50.8)              111 132 (51.0)       123 788 (51.4)       \<0.001
    LCX                                   54 314 (25.8)               55 638 (25.5)        60 444 (25.1)        \<0.001
    Bypass graft                          2163 (1.0)                  1189 (0.5)           1202 (0.5)           \<0.001
  Procedure details                                                                                             
   Approach                                                                                                     \<0.001
    Transradial                           127 686 (60.6)              138 397 (63.5)       161 104 (66.9)       
    Transfemoral                          71 473 (33.9)               67 668 (31.0)        67 166 (27.9)        
    Others (eg, brachial)                 11 376 (5.4)                11 924 (5.5)         12 378 (5.1)         
   Device                                                                                                       
    Thrombus aspiration\*                 21551/39140 (55.1)          21640/40050 (54.0)   22605/41740 (54.2)   \<0.001
    Distal protection                     7392 (3.5)                  8077 (3.7)           7519 (3.1)           \<0.001
    Rotablator                            7294 (3.5)                  7686 (3.5)           8910 (3.7)           \<0.001
    Drug-eluting balloon                  12 922 (6.1)                15 769 (7.2)         22 916 (9.5)         \<0.001
   Stent characteristics                                                                                        
    Type of stent                                                                                               
    Drug-eluting stent                    166 194 (78.9)              184 327 (84.6)       206 323 (85.7)       \<0.001
    Bare metal stent                      14 854 (7.1)                7807 (3.6)           4966 (2.1)           \<0.001
   TIMI flow (post-procedure)                                                                                   
    Flow 3                                205 978 (97.8)              213 709 (98.0)       235 969 (98.1)       \<0.001

\*Confined to patients with STEMI.

CABG, coronary artery bypass grafting; LAD, left anterior descending; LCX, left circumflex; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-elevation myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction.

From the derivation cohort, we developed two separate PCI risk prediction models for estimating in-hospital mortality that can be applied to both acute and elective clinical settings: one based on all available variables including both preprocedure and procedure-related variables (full model) and the other based on preprocedural variables only (preprocedure model). In addition, an integer score was assigned to each variable selected in the preprocedure model in proportion to the estimated regression coefficient (0.23) defined from an incremental risk ratio by age (10 years). The regression coefficient for each level of every risk factor was subsequently divided by this reference value (0.23) to compute its weights for the risk score.[@R17]

Using the validation cohort, the performance of the developed models was examined by using C-statistics to assess discrimination and by demonstrating calibration plots to evaluate calibration. After assessing discrimination and calibration across the entire validation cohort, we examined the model performance for clinically distinct patient populations. These included acute coronary syndrome (ACS) versus non-ACS, female versus male and advanced age (\>70) versus younger age (≤70).

All variables had less than 3% missingness. To account for missing data, single imputation was used for each variable; 'STEMI' for type of MI, 'transradial' for access site and 'no' for others. Data were analysed using R, V.3.3.3 (R Foundation for Statistical Computing, Vienna, Austria). All p values were two sided, and p values \<0.05 were considered significant.

Patient and public involvement {#s2d}
------------------------------

Patients and public were not involved in this study.

Results {#s3}
=======

Population characteristics {#s3a}
--------------------------

After excluding patients with missing data on age and/or sex (n=3410), outside the age range of 20--100 years (n=281), with missing data on outcomes (n=647), and with missing data on diagnosis (n=43), 669 181 patients from 1018 institutes were included in the analysis ([figure 1](#F1){ref-type="fig"}). The baseline demographic data, lesion characteristics and procedure details are summarised in [table 1](#T1){ref-type="table"}, while in-hospital outcomes are shown in [table 2](#T2){ref-type="table"}, stratified by enrolment year. About 40% of PCIs were performed in patients with ACS, while 3% of patients developed cardiogenic shock within 24 hours prior to PCI. During the index hospitalisation, 4788 (0.7%) patients died after PCI. The bivariate relationships between patient characteristics and in-hospital mortality are shown in the online [supplementary tables](#SP1){ref-type="supplementary-material"} (online [supplementary eTable 1](#SP1){ref-type="supplementary-material"} for the derivation cohort and online [supplementary eTable 2](#SP1){ref-type="supplementary-material"} for the validation cohort).
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###### 

Crude outcomes by enrolment year

                              Japanese PCI (J-PCI) 2014   J-PCI 2015   J-PCI 2016   P value
  --------------------------- --------------------------- ------------ ------------ ---------
  In-hospital death           1523 (0.7)                  1479 (0.7)   1786 (0.7)   0.033
  Bleeding complication       546 (0.3)                   701 (0.3)    779 (0.3)    \<0.001
   Access site bleeding       334 (0.2)                   429 (0.2)    460 (0.2)    0.007
   Non-access site bleeding   223 (0.1)                   287 (0.1)    341 (0.1)    0.003
  Periprocedural MI           875 (0.4)                   921 (0.4)    1140 (0.5)   0.005
  Tamponade                   317 (0.2)                   287 (0.1)    350 (0.1)    0.234
  Postprocedure shock         1920 (0.9)                  1927 (0.9)   2145 (0.9)   0.603
  Acute stent thrombosis      407 (0.2)                   331 (0.2)    297 (0.1)    \<0.001
  Emergent operation          206 (0.1)                   213 (0.1)    204 (0.1)    0.246

MI, myocardial infarction.

Between 2014 and 2016, demographics and risk factors of patients undergoing PCI did not change in terms of clinically meaningful difference. With regard to the diagnosis at the time of PCI, the proportion of patients with silent ischaemic heart disease slightly increased from 15.9% in 2014 to 17.4% in 2016, whereas the proportion of patients who underwent PCIs as treatment for STEMI decreased from 18.6% to 17.3% (p values for trend \<0.001). Procedures significantly changed during the study period. The rate of transradial approach increased significantly from 60.6% to 66.9%, in parallel with the decreasing trend of transfemoral approach (p values for trend \<0.001). Similarly, the use of a drug-eluting balloon and drug-eluting stent showed an increasing trend, whereas the use of bare metal stent decreased significantly (all p values for trend \<0.001). In patients with STEMI, the use of thrombus aspiration remained stable during the study period, although its trend demonstrated a significant increase (p value for trend=0.011).

Development of full and preprocedure models {#s3b}
-------------------------------------------

[Table 3](#T3){ref-type="table"} shows the results of the multivariable logistic regression analyses. Preprocedure variables selected in the final models were age, sex (female), STEMI, NSTEMI, unstable angina, previous PCI, previous coronary artery bypass grafting, hypertension, dyslipidaemia, smoker, renal dysfunction (renal dysfunction without requiring dialysis and renal dysfunction on dialysis), peripheral vascular disease, previous heart failure and cardiogenic shock within 24 hours prior to the procedure. All angiographic information, such as three-vessel disease, left main trunk lesion and involvement of left anterior descending artery or left main trunk as a target lesion, was retained in the full model.

###### 

Full and preprocedure risk model

                                          Full model   Preprocedure model                                                              
  --------------------------------------- ------------ -------------------- -------------- --------- ----------- ------ -------------- ---------
  Intercept                               −8.878621                                                  −8.472575                         
  Demographics                                                                                                                         
   Age, per 1 year                        0.023744     1.02                 1.02 to 1.03   \<0.001   0.023608    1.02   1.02 to 1.03   \<0.001
   Female                                 0.177372     1.19                 1.08 to 1.32   \<0.001   0.155252    1.17   1.06 to 1.29   0.002
  Diagnosis                                                                                                                            
   STEMI                                  2.528622     12.5                 10.7 to 14.7   \<0.001   2.530134    12.6   10.7 to 14.7   \<0.001
   NSTEMI                                 2.170769     8.77                 7.24 to 10.6   \<0.001   2.260405    9.59   7.93 to 11.6   \<0.001
   Unstable angina                        1.108935     3.03                 2.50 to 3.68   \<0.001   1.163039    3.2    2.64 to 3.88   \<0.001
  Risk factors                                                                                                                         
   Previous PCI                           −0.121767    0.89                 0.79 to 0.99   0.029     −0.170187   0.84   0.76 to 0.94   0.002
   Previous CABG                          0.371319     1.45                 1.17 to 1.79   \<0.001   0.38463     1.47   1.19 to 1.81   \<0.001
   Hypertension                           −0.181962    0.83                 0.76 to 0.91   \<0.001   −0.175804   0.84   0.77 to 0.92   \<0.001
   Dyslipidaemia                          −0.55876     0.57                 0.52 to 0.63   \<0.001   −0.540339   0.58   0.53 to 0.64   \<0.001
   Current smoker                         −0.19942     0.82                 0.74 to 0.91   \<0.001   −0.210493   0.81   0.73 to 0.90   \<0.001
   Renal insufficiency without dialysis   0.522425     1.69                 1.51 to 1.88   \<0.001   0.552934    1.74   1.56 to 1.93   \<0.001
   Renal insufficiency on dialysis        0.827209     2.29                 1.95 to 2.69   \<0.001   0.821163    2.27   1.94 to 2.67   \<0.001
   Peripheral vascular disease            0.457832     1.58                 1.35 to 1.85   \<0.001   0.498317    1.65   1.41 to 1.92   \<0.001
   Previous heart failure                 0.451346     1.57                 1.40 to 1.77   \<0.001   0.491731    1.64   1.45 to 1.84   \<0.001
   Cardiogenic shock within 24 hours      2.540633     12.7                 11.6 to 13.9   \<0.001   2.67607     14.5   13.3 to 15.9   \<0.001
  No of diseased vessels                                                                                                               
   Three-vessel disease                   0.368771     1.45                 1.31 to 1.60   \<0.001                                     
   Left main trunk                        0.680996     1.98                 1.75 to 2.23   \<0.001                                     
  Lesion location                                                                                                                      
   LAD/left Main                          0.527633     1.69                 1.55 to 1.86   \<0.001                                     

CABG, coronary artery bypass grafting; LAD, left anterior descending; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.

Discrimination and calibration performance of full and preprocedure models {#s3c}
--------------------------------------------------------------------------

In the entire validation cohort, discrimination performance of the full model was excellent, with C-index of 0.929 (95% CI 0.924 to 0.935). The exclusion of the angiographic information from the full model resulted in only a slight decrement in the overall model discriminatory performance, and the C-index of the preprocedure model was 0.926 (95% CI 0.920 to 0.931). Both full and preprocedure models performed well even in the prespecified subgroups, and C-indexes ranged from 0.829 to 0.933 for the full model and from 0.820 to 0.926 for the preprocedure model, respectively (online [supplementary eTable 3](#SP1){ref-type="supplementary-material"}). There was excellent calibration performance of both models in the entire validation cohort (online [supplementary eFigure 1](#SP1){ref-type="supplementary-material"}. The calibration performance was also acceptable in the prespecified subgroups, although both models were likely to underestimate the risk of mortality in high-risk patients who underwent the elective procedure (online [supplementary eFigure 2](#SP1){ref-type="supplementary-material"}).

Development and validation of integer simple risk score {#s3d}
-------------------------------------------------------

The integer points for each variable derived from beta coefficients in the multivariable models are listed in [figure 2](#F2){ref-type="fig"}. The highest number of points was 12 (cardiogenic shock), whereas the lowest was −3 (dyslipidaemia). The possible total points ranged from −6 to 43. The agreements between the observed and estimated risks of mortality with the developed risk-scoring methods were assessed across five groups in the entire validation cohort ([figure 2](#F2){ref-type="fig"}). Overall, the agreements were acceptable, although the integer score underestimated mortality risk in the higher risk patients, where the observed and predicted mortalities were 1.2% and 0.9% in the second highest risk group, and 6.9% and 6.6% in the highest risk group, respectively.

![Integer score and its calibration performance. The agreements between the observed and expected risks of mortality with the developed integer score were assessed across five groups of the total points in the validation cohort. CABG, coronary artery bypass grafting; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.](bmjopen-2018-026683f02){#F2}

Discussion {#s4}
==========

Using the nationally representative cohort of Japanese patients who underwent PCI with \>660 000 procedures from 1018 institutes, we developed and internally validated risk models predicting in-hospital mortality in patients after PCI. The final full model included age, sex, clinical presentation, previous PCI, previous coronary artery bypass grafting, hypertension, dyslipidaemia, smoker, renal dysfunction, peripheral vascular disease, previous heart failure, cardiogenic shock within 24 hours prior to the procedure and angiographic information. The model performed very well in an independent validation cohort, as well as in various subgroups stratified by age, sex and clinical presentation. The model performance was retained even after excluding angiographic information, and a simplified integer risk score based on the preprocedure model also performed well. These developed risk prediction models provided the risk-adjusted mortality in benchmark report, compared an institution's performance with that of national experience and stratified patients who were at risk preprocedurally.

For the purpose of risk adjustment for benchmarking and comparing institutional performances, rigorous adjustment is warranted. Significant differences were observed in patient demographics, biological response to medication or procedure and practice pattern in PCI between Japan and the Western countries.[@R10] For example, patients in Japan are likely to have more advanced age, have lower body mass weight and experience bleeding complications than those in Western countries. Furthermore, the proportion of elective PCIs performed in Japan is greater than those in other countries. With regard to practice patterns, thrombus aspiration is still widely performed as treatment for patients with STEMI despite the recent downgrade of the relevant recommendations in the USA and European guidelines.[@R20] In spite of these significant differences, some risk models or clinical scores that are derived from the Western countries have been externally validated and were proven useful in Japanese patients.[@R10] Kohsaka *et al* applied the in-hospital mortality risk model derived from the National Cardiovascular Data Registry CathPCI Registry, which is the nationwide PCI registry in the USA, to the regional PCI registry from 15 Japanese institutes near Tokyo area and demonstrated that the US model was clinically applicable in Japanese population with excellent discrimination and acceptable calibration performances.[@R10] However, given its limited calibration performance in high-risk patients, the risk model derived from its own dataset can provide an accurate adjusted mortality.

A number of risk models were developed from various registries to predict risk of mortality in patients undergoing PCI. Individual components varied among risk models, but several components, such as age, clinical presentation or urgency, renal dysfunction and cardiogenic shock, were consistently included in the model.[@R4] Our developed risk models also allied with the previous models and included these core variables. Although angiographic information also served as a component of our full model, its incremental predictive value may be limited, given the sufficient performance of the preprocedure model. This finding is consistent with those of previous studies, and Peterson *et al* showed that in-hospital mortality was driven primarily by pre-existing patient comorbidities and makers of clinical instability.[@R4] It allows patients and physicians to obtain a reasonable estimate of mortality preprocedurally.

Few studies reported the risk model predicting mortality after PCI derived from Japanese population. Tanaka *et al* developed the Kyoto model using the CREDO-Kyoto Registry, which is one of the most established PCI registries in Japan.[@R24] However, the Kyoto model intended to predict long-term mortality after revascularisation and was not applicable to patients undergoing PCI for MI, because the dataset excluded patients who experienced acute MI 1 week prior to the index procedure. Furthermore, the dataset included patients who underwent revascularisation between 2000 and 2002 and could not be directly applied to current practice. Our study is the first to report the risk model predicting in-hospital mortality in Japan using the nationwide PCI registry in the contemporary PCI practice. Thus, the Japanese cardiovascular society can use this model as an instrument for the pre-PCI risk stratification and to distribute the risk-adjusted mortality in benchmark reports, leading to improve quality of care and clinical outcomes in PCI.

Several variables, such as prior PCI, hypertension, dyslipidaemia and current smoker, were identified as independent factors associated with a reduction in mortality. Although some controversies remain and they may be attributed to the confounding factors, their associations with improved mortality were consistent with those of previous studies.[@R4] Smoker's paradox is a well-known phenomenon and has been reported in patients undergoing PCI.[@R26] Recent data have demonstrated a specific pharmacodynamic enhancement of platelet inhibition by clopidogrel among smokers,[@R28] which may hold important implications for patients treated with PCI, given that clopidogrel is still widely used for patients treated with PCI in Japan.[@R19] The protective effect of dyslipidaemia may be related to statin use before PCI, which our database does not collect as a separate variable. The diagnosis for dyslipidaemia may have acted as a proxy for statin use, which has been shown to reduce the risk of postprocedural MI and mortality in previous meta-analysis studies. Meta-analysis demonstrated that statin administration before PCI significantly reduced the risk of postprocedural MI, resulting in the reduction in mortality.[@R29] The impact of pre-existing hypertension on in-hospital mortality remains controversial; however, a recent study from the Acute Myocardial Infarction in Switzerland Plus Registry reported that pre-existing hypertension was associated with increased risk of in-hospital mortality in patients presenting with ACS.[@R31] Although the exact mechanism is unknown, pretreatment of hypertension with beta-blockers and renin--angiotensin--aldosterone inhibitors could have led to a favourable outcome. Previous studies have consistently demonstrated the protective effect of prior PCI in terms of reduction in in-hospital mortality in patients undergoing PCI.[@R4] This may be attributed to the fact that patients with prior PCI were more likely to undergo subsequent 'low-risk' PCI, such as staged PCI. In contrast, those with prior CABG were more likely to undergo subsequent 'high-risk' PCI, such as PCI for multivessel lesion, left main trunk lesion and severely calcified lesion, resulting in an increased risk of in-hospital mortality.

Limitations {#s4a}
-----------

This study had several limitations. First, J-PCI is a voluntary registry; the contributing hospitals may have a larger procedure volume than the average institutes in Japan. However, J-PCI included \>85% of all PCIs performed in Japan and assured a high participation rate by linking to the application for board certification and renewal. Second, improving the quality of the database is a continuing issue in J-PCI. With regard to data accuracy, not only is data auditing important but also the education of persons inputting data at each site as it enables adherence to correct data definitions. Third, the candidate variables for the risk models were limited to those available in J-PCI. Actually, several variables selected in other risk models were not included in our dataset and may further refine risk prediction.

Fourth, the models underestimated the risk of mortality in high-risk patients who underwent the elective procedure, although their discrimination and calibration performances were acceptable. Although the exact reason remains unknown, lack of granularity for variables representing the complexity of PCI, such as SYNTAX score, chronic total occlusion and severity of calcification, may have led to the suboptimal calibration performance in this particular population. Since the developed risk models cover patients with a broad range of mortality risk, providing an accurate estimation for all patients is challenging, especially in low-risk patients, mainly owing to the small number of in-hospital deaths. Further studies may be required to generate separate models for patients with specific clinical presentations to improve risk prediction.

Fifth, the models have been validated using only J-PCI data; it has not been validated on an external dataset. Finally, J-PCI captured in-hospital outcomes that occurred only during hospitalisations where PCIs were performed; therefore, data on the subsequent outcomes when the patients were transferred to other hospitals and facilities were lacking. This may have led to the underestimation of mortality in J-PCI. We have recently launched a project involving selected institutes participating in J-PCI, aiming to obtain long-term follow-up data, which may provide additional insights.

Conclusion {#s5}
==========

Using the nationwide Japanese-PCI registry, we have developed and internally validated the risk models for predicting in-hospital mortality after PCI. The models performed very well in a broad spectrum of patients undergoing PCI as well as in clinically important subgroups. These models are expected to help improve the rate of patient mortality after PCI by facilitating pre-PCI risk stratification, improving hospital quality assessment and providing an accurate adjusted risk in benchmark reports.
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